Bell Investment Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bell Investment Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9	Closed	-$529	–	1961
2023 Q4	$529	Buy	+9	New	+$506	﹤0.01%	1814
2023 Q3	–	Sell	-12	Closed	-$434	–	2014
2023 Q2	$434	Sell	12 -12	-50%	-$494	﹤0.01%	1880
2023 Q1	$893	Buy	+24	New	+$1.08K	﹤0.01%	1615
2022 Q4	–	Sell	-15	Closed	-$1K	–	2051
2022 Q3	$1K	Buy	15 +7	+88%	+$518	﹤0.01%	1664
2022 Q2	$1K	Buy	+8	New	+$509	﹤0.01%	1687
2021 Q4	–	Sell	-8	Closed	-$1K	–	1984
2021 Q3	$1K	Buy	+8	New	+$1.29K	﹤0.01%	1650

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bell Investment Advisors's MRTX Position: Q1 2024 in Review

Bell Investment Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 9 shares — an estimated $529 sold.

Bell Investment Advisors first reported a position in MRTX in Q3 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Bell Investment Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bell Investment Advisors sold 9 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $529.
Bell Investment Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Bell Investment Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bell Investment Advisors's 13F filing for Q1 2024, filed 8 May 2024.